X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (28591) 28591
Newspaper Article (4673) 4673
Publication (3426) 3426
Patent (2275) 2275
Newsletter (521) 521
Book Review (355) 355
Trade Publication Article (333) 333
Magazine Article (186) 186
Book Chapter (125) 125
Web Resource (68) 68
Conference Proceeding (39) 39
Dissertation (37) 37
Government Document (26) 26
Book / eBook (10) 10
Transcript (10) 10
Data Set (6) 6
Paper (2) 2
Presentation (2) 2
Report (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mutation (22227) 22227
humans (17949) 17949
index medicus (17117) 17117
oncology (14408) 14408
cancer (10044) 10044
lung cancer (8800) 8800
female (8567) 8567
male (7120) 7120
tumors (6916) 6916
genetic aspects (6604) 6604
chemotherapy (6021) 6021
middle aged (5917) 5917
research (5902) 5902
aged (5375) 5375
epidermal growth factor (5162) 5162
lung neoplasms - genetics (5152) 5152
gefitinib (5148) 5148
mutations (5091) 5091
kinases (4859) 4859
cancer therapies (4788) 4788
metastasis (4733) 4733
animals (4644) 4644
receptor, epidermal growth factor - genetics (4573) 4573
adult (4329) 4329
egfr (4315) 4315
care and treatment (4000) 4000
proteins (3760) 3760
lung neoplasms - drug therapy (3706) 3706
gene mutations (3662) 3662
patients (3631) 3631
prognosis (3494) 3494
lung neoplasms - pathology (3489) 3489
lung cancer, non-small cell (3388) 3388
gene expression (3383) 3383
adenocarcinoma (3357) 3357
carcinoma, non-small-cell lung - genetics (3314) 3314
cell line, tumor (3186) 3186
health aspects (3182) 3182
expression (3178) 3178
medicine (3175) 3175
analysis (3174) 3174
biochemistry (3126) 3126
growth-factor receptor (3070) 3070
colorectal cancer (3038) 3038
carcinoma, non-small-cell lung - drug therapy (2954) 2954
cell biology (2897) 2897
research article (2879) 2879
signal transduction (2871) 2871
aged, 80 and over (2806) 2806
genes (2745) 2745
erlotinib (2694) 2694
deoxyribonucleic acid--dna (2664) 2664
multidisciplinary sciences (2642) 2642
antineoplastic agents - therapeutic use (2631) 2631
pathology (2630) 2630
cell lung-cancer (2602) 2602
medical prognosis (2574) 2574
chemistry (2571) 2571
mice (2562) 2562
survival (2497) 2497
studies (2480) 2480
microbiology (2409) 2409
medical research (2368) 2368
enzymology (2339) 2339
article (2278) 2278
beer (2277) 2277
wine (2277) 2277
metallurgy (2275) 2275
mutation or genetic engineering (2275) 2275
spirits (2275) 2275
vinegar (2275) 2275
receptor, epidermal growth factor - antagonists & inhibitors (2259) 2259
breast cancer (2233) 2233
receptor, epidermal growth factor - metabolism (2216) 2216
development and progression (2182) 2182
non-small cell lung cancer (2177) 2177
acquired-resistance (2158) 2158
therapy (2140) 2140
carcinoma, non-small-cell lung - pathology (2118) 2118
apoptosis (2092) 2092
epidermal growth factor receptors (2066) 2066
science (2051) 2051
respiratory system (2042) 2042
biomarkers (2039) 2039
adenocarcinoma - genetics (2034) 2034
protein kinase inhibitors - therapeutic use (2017) 2017
mutation - genetics (1987) 1987
biochemistry & molecular biology (1962) 1962
genetics (1952) 1952
resistance (1930) 1930
immunohistochemistry (1927) 1927
open-label (1913) 1913
epidermal growth factor receptor (1853) 1853
clinical trials (1840) 1840
tyrosine (1832) 1832
phosphorylation (1828) 1828
treatment outcome (1821) 1821
genomes (1766) 1766
egfr mutations (1719) 1719
biology (1711) 1711
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (36389) 36389
French (1138) 1138
German (418) 418
Russian (83) 83
Spanish (35) 35
Polish (30) 30
Czech (28) 28
Chinese (21) 21
Hungarian (19) 19
Portuguese (15) 15
Danish (11) 11
Slovenian (11) 11
Croatian (7) 7
Greek (7) 7
Hebrew (6) 6
Dutch (5) 5
Serbian (5) 5
Norwegian (4) 4
Slovak (3) 3
Turkish (3) 3
Italian (2) 2
Lithuanian (2) 2
Persian (2) 2
Ukrainian (2) 2
Japanese (1) 1
Latvian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1800 - 1805
We proposed to compare the outcomes of first‐line epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI) alone with EGFR‐TKI plus whole‐brain... 
EGFR mutation | radiotherapy | prognosis | Brain metastasis | lung adenocarcinoma | CANCER PATIENTS | GEFITINIB | PHASE-II | RADIATION-THERAPY | TKI | ONCOLOGY | MUTATIONS | ERLOTINIB | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Brain Neoplasms - secondary | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Brain Neoplasms - mortality | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Proportional Hazards Models | Treatment Outcome | Combined Modality Therapy | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Brain Neoplasms - therapy | Radiotherapy - methods | Aged | Mutation | Neoplasm Staging | Adenocarcinoma - mortality | Adenocarcinoma | Tyrosine | Brain | Medical research | Care and treatment | Epidermal growth factor | Lung cancer | Brain tumors | Medicine, Experimental | Phenols | Metastasis | Radiotherapy | Medical imaging | Epidermal growth factor receptors | Brain cancer | Oncology | Nervous system | Radiation therapy | Cancer therapies | Survival | Patients | Disease control | Metastases | Studies | Survival analysis | Neurotoxicity | Clonal deletion | Medical prognosis | Response rates | Protein-tyrosine kinase | Original
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 108, pp. 29 - 37
Highlights • Cranial metastases are frequent sites of progression. • Surgery, stereotactic radiosurgery and/or WBRT has been the cornerstone of therapy. •... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | CNS metastases | BLOOM trial | Osimertinib | AZD3759 | Tyrosine kinase inhibitors | Non-small cell lung cancer | IMMUNE CHECKPOINT INHIBITORS | PHASE-III | WHOLE-BRAIN RADIOTHERAPY | OPEN-LABEL | DOSE WEEKLY ERLOTINIB | CELL LUNG-CANCER | NERVOUS-SYSTEM METASTASES | STEREOTACTIC RADIOSURGERY | ONCOLOGY | RESPIRATORY SYSTEM | LEPTOMENINGEAL CARCINOMATOSIS | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Treatment Outcome | Combined Modality Therapy | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Central Nervous System Neoplasms - secondary | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Central Nervous System Neoplasms - drug therapy | Medical colleges | Usage | Care and treatment | Metastasis | Lung cancer, Non-small cell | Radiosurgery | Tyrosine | Chemotherapy | Cancer
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2012, Volume 2, Issue 10, pp. 922 - 933
EGFR-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs). The combination of EGFR-TKI afatinib and... 
lung cancer | EGFR tyrosine kinase inhibitors | afatinib | EGFR mutations | erlotinib | HER2 amplification | cetuximab | EGFR T790M | acquired resistance
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2013, Volume 8, Issue 3, pp. 346 - 351
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 05/2012, Volume 2, Issue 5, pp. 458 - 471
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 06/2011, Volume 6, Issue 6, pp. 1006 - 1015
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2013, Volume 19, Issue 8, pp. 2240 - 2247
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 104, pp. 58 - 64
Highlights • Providing clinical evidence of EGFR-TKI retreatment following chemotherapy. • Survival benefit was pronounced in patients with longer drug... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Adenocarcinoma | EGFR mutation | Drug holiday | Lung cancer | Progression free survival | EGFR TKI retreatment | Exon 21 mutation | Females | Overall survival | NSCLC | ACQUIRED-RESISTANCE | INITIAL GEFITINIB | CHEMOTHERAPY | TRIAL | TKI | ONCOLOGY | CLINICAL BENEFIT | RESPIRATORY SYSTEM | EGFR TK1 retreatment | QUALITY-OF-LIFE | AFATINIB | ERLOTINIB | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Thyroid Nuclear Factor 1 | Adenocarcinoma - pathology | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - pathology | Exons - genetics | Treatment Outcome | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Nuclear Proteins | Disease-Free Survival | Retreatment | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Transcription Factors | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Care and treatment | Chemotherapy | Oncology, Experimental | Research | Lung cancer, Non-small cell | Medicine, Preventive | Epidemiology | Cancer | Preventive health services | Analysis | Phenols
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2014, Volume 9, Issue 9, pp. 1345 - 1353
Journal Article